Israeli medical technology company P-Cure and Indian healthcare company ARISTION Proton Centre have announced the signing of a binding agreement to deploy P-Cure's compact, synchrotron-based proton therapy systems in India.
ARISTION plans a long-term investment of approximately Rs 1,900 crore to build dedicated proton therapy infrastructure across the country.
The first centre will be established at Sentient Health City, Bengaluru, ARISTION's flagship 660-bed quaternary campus built around integrated artificial intelligence (AI) and augmented care solutions, followed by centres in Kochi and a third major metropolitan city.
Together, the three centres form the initial phase of a wider national proton therapy network. For the Kochi centre, ARISTION is actively seeking a joint venture partner, while evaluation of locations and partners for the third proton centre is underway.
Across the network, care will be built on an integrated AI and augmented intelligence layer, with Surgy.health, a new-age AI operational layer for hospitals, as the AI technology partner for the ARISTION group, spanning hospital operations, clinical workflows, and patient experience.
Conventional proton therapy facilities typically demand vast infrastructure footprints and heavy capital expenditure — costs that are ultimately passed on to patients. P-Cure's ultracompact, synchrotron-based system is engineered around a dramatically smaller footprint and materially lower operating costs, with no compromise on clinical capability.
The agreement marks the first deployment of P-Cure's ultracompact proton therapy system in India. The planned investment is intended to fund an integrated network of centres rather than standalone machine installations, with affordability and geographic access positioned at the centre of the model.
